Research & Development: Page 74
-
PharmaVoice Team/PharmaVoice
The Researchers & SCIENTISTS
Dr. Lee Babiss was the captain of his Ultimate Frisbee team in college. A consummate life-sciences professional, Dr. Lee Babiss, Global Head of Pharma Research at Roche, is an insightful scientist with a love for research and a passion for patients. Dr. Lee Babiss, Roche Dr. Larry Blankstein, Gen...
By PharmaVoice Team • July 28, 2009 -
PharmaVoice Team/PharmaVoice
The CHANGE agents
Vaughn Anthony, D. Anderson & Co. Jeffrey Berkowitz, Schering-Plough Pharmaceuticals Debbie Botwick, Pfizer Oliver Chateau, GlaxoSmithKline Nancy Corkum, Johnson & Johnson Michelle Dipp, GSK initiative Mary Hensley Evans, imc2 Health and Wellness Frederick Foard, Communications Media Inc....
By PharmaVoice Team • July 28, 2009 -
Explore the Trendline➔
Stock via Getty Images
TrendlineOncology R&D
Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
The ENTREPRENEURS
Michael Beckloff, Beckloff Associates Dr. Joan Bradley, The JB Ashtin Group Faruk Capan, Intouch Solutions Gary Beer, DOV Pharmaceutical, Inc. Ron Cohen, Acorda Therapeutics Inc. Elizabeth Apelles, Greater than One Jaswinder Chadha, marketRx Denise Deman-Williams, Bench International Jay Deakins,...
By PharmaVoice Team • July 28, 2009 -
PharmaVoice Team/PharmaVoice
Commanders & CHIEFS
Ahsan Awan, Global CINRG Inc. Ross Bjella, DDN Pharmaceutical Logistics Laurie Cooke, The Healthcare Businesswomen’s Association (HBA) John Farinacci, ResearchPoint Dr. Thomas Hughes, Zafgen Greg Johnson, Strategic Business Research Rick Keefer, Publicis Strategic Solutions Group Tuan Ha Ngoc, AV...
By PharmaVoice Team • July 28, 2009 -
PharmaVoice Team/PharmaVoice
Breaking Down The Complex
While the U.S. Food and Drug Administration has accelerated its review and approval of new medicines, drug developers’ increased focus on complex diseases, such as cancer and neurological disorders, as well as disorders for which there are few effective therapies, has resulted in longer clinical ...
By PharmaVoice Team • June 8, 2009 -
PharmaVoice Team/PharmaVoice
Table of Contents
Letter from the Editor The Forum Breaking Down the Complex: Regardless of the current economic climate and the increasing complexities and costs of drug development, the objective for clinical operations executives remains the same: identify the top people and most advanced technologies, and put ...
By PharmaVoice Team • June 8, 2009 -
PharmaVoice Team/PharmaVoice
Clinical Monitoring: How EDC Has Changed the Game
Clinical Monitoring: How EDC Has Changed the Game As the use of electronic data capture (EDC) systems increasingly becomes mainstream in clinical research, replacing the use of paper CRFs, much focus has been placed on the revolutionary impact this technology has had on the role of clinical da...
By PharmaVoice Team • June 8, 2009 -
PharmaVoice Team/PharmaVoice
Adapting to Meet Today's Needs
From the FDA to the top 20 global biopharmaceutical companies, service providers, and care givers everyone is searching for ways to improve process, procedures, and margins. No one is spared from the impact of our economic situation today and the market is demanding greater focus on quality and s...
By PharmaVoice Team • June 8, 2009 -
PharmaVoice Team/PharmaVoice
Metrics Predict Success for Clinical Trials
A CenterWatch survey says 70% of clinical trials run late, something that has changed little over the years. In response, the clinical trial industry is making better use of metrics that improve feasibility planning and selection of trial sites. Metrics to Improve Trial Feasibility Assessment Al...
By PharmaVoice Team • June 8, 2009 -
PharmaVoice Team/PharmaVoice
Maintaining Clinical Operations in a Downward Economy: It's Just Good Business
As pharmaceutical, biotechnology, and medical-device companies look to realize cost-efficiencies across the board to meet the demands of the current fiscal crisis, they should evaluate the consequences of budget cuts and staff attrition as they reorganize their clinical departments. While some am...
By PharmaVoice Team • June 8, 2009 -
PharmaVoice Team/PharmaVoice
An Albatross and an Opportunity
Economic necessity is driving our industry to look hard at how more efficient services and systems can be provided to support the clinical research process. There are those who would say this necessity was present before the recent economic meltdown. However, I have personally been involved in cl...
By PharmaVoice Team • June 8, 2009 -
PharmaVoice Team/PharmaVoice
You Can't Teach People to Care or Can You?
Today, we easily recognize terrorism, pandemic flu, and hurricanes as potential disasters …the latter being an event that we in New Orleans know all too well. A hurricane named Katrina was our disaster…and a vivid example of how a lack of preparation and structural-weakness can eventually be cata...
By PharmaVoice Team • June 8, 2009 -
PharmaVoice Team/PharmaVoice
Supplier Showcase
Aptuit, Inc. Two Greenwich Office Park Greenwich, CT 06831 Phone: 203-422-6600 Fax: 203-422-0266 www.aptuit.com World-Class Clinical Operations Aptuit’s Clinical Operations are focused on the critical steps that are essential in taking a novel compound and developing it into a safe and effe...
By PharmaVoice Team • June 8, 2009 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
Beyond the clouds At the moment, it can be difficult for drug developers to see beyond the economic cloud that currently shrouds the pharma industry. Based on her interviews with several pharmaceutical research and development executives, Carolyn Gretton, writer of this month’s Forum, reports th...
By PharmaVoice Team • June 8, 2009 -
PharmaVoice Team/PharmaVoice
Last Word
Madeira Therapeutics’ Peter Joiner Presents a Case for the Pediatric Market In the pediatric setting, I believe that Madeira as well as others committed to this arena have the responsibility of educating physicians as to how a drug should be used and what role it plays in a patient’s life. Peter ...
By PharmaVoice Team • May 25, 2009 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharmaceutical POOL Kurt HARTMAN Dr. Craig HOPKINSON New Hires at Eisai Eisai Inc., a U.S. pharmaceuti cal subsidiary of Japan’s Eisai Co. Ltd., has appointed Kurt Hart man, J.D., senior director of value and access, with responsibility for integrating and aligning Eisai’s focus on reimbursement ...
By PharmaVoice Team • May 25, 2009 -
PharmaVoice Team/PharmaVoice
E-Media
Symyx Grants ACCESS TO MOLECULE INFORMATION The Biotechnology Industry Organization (BIO) has launched the BIO Community (community.convention.bio.org) to provide free resources to biotechnology leaders and professionals in an effort to help them overcome the chal lenges currently facing the indu...
By PharmaVoice Team • May 25, 2009 -
PharmaVoice Team/PharmaVoice
What's New
Vincent Aurentz, executive VP of portfolio devel opment, says this activity complements the compa ny’s tool kit of collaborative approaches to build a highquality portfolio with partners. “The creation of a venture capital fund under lines our commitment to be a best partner for biotech entrepren...
By PharmaVoice Team • May 25, 2009 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Pharma R&D Spending Remains Robust Despite Tough Economy Despite the current economic downturn, pharmaceutical research and development spending continues to play a vital role in the pharmaceutical industry. According to a recent report by CBR Pharma Insights, recent trends indicate a consoli...
By PharmaVoice Team • May 25, 2009 -
PharmaVoice Team/PharmaVoice
PharmaOutlet
You are planning an upcoming investigators meeting. Going over your checklist, you check off sponsor, project manager, central laboratory, site coordinators, site monitors, principal investigators, and others involved in the research. Flights, hotel accommodations, and meals also have been arrang...
By Lynn Meyer • May 25, 2009 -
PharmaVoice Team/PharmaVoice
ACRP 2009 Wrap Up
ACRP 2009 Global Conference & Exhibition — Denver, April 24-28 A record crowd of about 3,000 attended the Association of Clinical Research Professionals (ACRP) 2009 Global Conference & Exhibition in Denver in April. Held in conjunction with the Academy of Pharmaceutical Physicians and Inv...
By PharmaVoice Team • May 25, 2009 -
PharmaVoice Team/PharmaVoice
Annual DIA Preview Showcase
SPECIAL FEATURE DIA 45TH ANNUAL MEETING We all share in the responsibility to work together to strengthen the science used in pharmaceutical product development, evaluation, and review,” says Program Chair Nancy Smith, Ph.D., former director of the Office of Training and Communications, CDER, at ...
By PharmaVoice Team • May 25, 2009 -
PharmaVoice Team/PharmaVoice
Meet the Chief Scientific Officers
The CSO Role The chief scientist officer helps set a company’s strategy, interacts with investors and board of directors, and helps people understand the science behind new products. MCKERNAN. PFIZER. A CSO at Pfizer handles everything from the idea to proof of concept, establishing and building ...
By Denise Myshko • May 23, 2009 -
PharmaVoice Team/PharmaVoice
Upfront
UPFRONT Milestones 20TH ANNIVERSARY John R. Vogel Associates Inc. celebrates 20 years of assisting pharmaceutical and biopharmaceutical companies and the pharmaceutical service providers to enhance results achieved through outsourcing and strategic alliances. Mr. Vogel, who founded the company in...
By PharmaVoice Team • May 23, 2009 -
PharmaVoice Team/PharmaVoice
Defining a Career Path in the New Pharmaceutical Era
Avoiding the Bull’s-Eye When management needs to trim the workforce, there are ways to avoid being the target. The value of an employee increases if he or she has a can-do attitude, is a problem solver, and can react quickly to changes and challenges in the business environment. Binner. AstraZene...
By Robin Robinson • April 27, 2009
Previous
